Genelux Employee Directory

Biotechnology ResearchCalifornia, United States11-50 Employees

Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery Platform is the foundation of our oncolytic immunotherapy development, having produced over 500 different versions of the vaccinia virus. Olvi-Vec, our lead product candidate is currently in a Phase 3 registrational clinical trial for Platinum-Resistant/Refractory Ovarian Cancer (PRROC). Olvi-Vec is also being developed in Non-Small Cell Lung Cancer (NSCLC), recurrent Small Cell Lung Cancer (SCLC), and recurrent Ovarian Cancer.
We are dedicated to advancing a pipeline of next-generation oncolytic immunotherapies that deliver the full complement of tumor neo-antigens with the power to stimulate a personalized immune response for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Information about our investigational products and clinical trials can be found here.
For more information, please visit https://genelux.com/ and follow us on Twitter @Genelux_Corp and Facebook @Genelux. 
Olvi-Vec is an investigational product candidate not yet approved by the US Food and Drug Administration.

Find Genelux employees' phone numbers or email addresses

Genelux Global Highlights

Location
Employees

North America
46

Minus sign iconPlus sign icon
  • United States Of America
    46

Africa
1

Minus sign iconPlus sign icon
  • Nigeria
    1

South America
1

Minus sign iconPlus sign icon
  • Uruguay
    1

Genelux's Leadership

  • Stylized image of a person
    P. S.
    Chief Medical Officer
    Phone icon
  • Stylized image of a person
    C. G.
    Vice President Program Management
    Phone icon
  • Stylized image of a person
    R. S.
    Head Of Regulatory
    Phone icon
  • Stylized image of a person
    Q. Z.
    Associate Vice President Of Regulatory Affairs
    Phone icon
  • Stylized image of a person
    S. H.
    Clinical Operations Specialist
    Phone icon
  • Stylized image of a person
    A. P.
    Clinical Trial Operations Associate
    Phone icon
  • Stylized image of a person
    K. D.
    Adminstrator Assistant
    Phone icon
  • Stylized image of a person
    T. H.
    Investor
    Phone icon

Genelux Employee Metrics

100%
50%
0%
2026
2025
2024
  • Accounting
  • Administrative
  • Community & Social Services
  • Education
  • Entrepreneurship
  • Other

Contact profiles from Genelux

Name
Title
Contact Info
Location
Last Update
  • Stylized image of a person
    J. T.
    Phone icon
    UNITED STATES
    Jul 13, 2023
  • Stylized image of a person
    J. P.
    Phone icon
    UNITED STATES
    Mar 07, 2023

Frequently Asked Questions

What is Genelux known for?

Minus sign iconPlus sign icon
Genelux was founded in 2001 operates in the Biotechnology Research industry. Explore Genelux's company overview page for more information.

What is Genelux's most common email format?

Minus sign iconPlus sign icon
Genelux employees' email format typically follows the pattern of . Trying to find reliable and up-to-date employee contact data? Find more Genelux email formats with LeadIQ.

How many employees does Genelux have currently?

Minus sign iconPlus sign icon
Genelux has approximately 34 employees as of January 2026. These team members are located across 3 continents, including North AmericaAfricaSouth America.

Who are Genelux's key employees and leadership?

Minus sign iconPlus sign icon

As of January 2026, Genelux's key employees include:

  • Chief Medical Officer: P. S.
  • Vice President Program Management: C. G.
  • Head Of Regulatory: R. S.
  • Associate Vice President Of Regulatory Affairs: Q. Z.
  • Clinical Operations Specialist: S. H.

Looking for contact data? Unlock accurate emails and phone numbers for your ideal prospects with LeadIQ.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.